Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins

被引:52
作者
Gimenez, F
Fernandez, C
Mabondzo, A
机构
[1] Univ Paris 11, Pharm Clin, F-92296 Chatenay Malabry, France
[2] CEA, Serv Pharmacol & Immunol, Gif Sur Yvette, France
关键词
HIV protease inhibitor; efflux protein; P-glycoprotein; blood-brain barrier; multidrug resistance; brain;
D O I
10.1097/00126334-200406010-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV protease inhibitors (HPIs) have limited penetration into the brain. This poor transport through the blood-brain barrier is mainly due to active efflux by proteins such as P-glycoprotein (P-gp) preventing drugs from clearing the brain of the virus. The present paper focuses on cerebral uptake of HPIs and interactions between HPIs and efflux proteins, either as substrates or modulators. Most of the studies described HPIs as P-gp substrates. Studies are more controversial when investigating HPIs as inhibitors of P-gp. HPIs seem to be able to inhibit efflux proteins of in vitro cell models but with limited consequences in vivo. Moreover, after repeated administrations of HPIs, most of them are also able to induce the expression and functionality of P-gp. For these reasons, certain combinations of HPIs may not efficiently increase brain uptake of HPIs as would combinations of more potent efflux inhibitors.
引用
收藏
页码:649 / 658
页数:10
相关论文
共 71 条
[1]   HIV-1-associated dementia: A metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes [J].
Anderson, E ;
Zink, W ;
Xiong, HG ;
Gendelman, HE .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S43-S54
[2]  
Bain LJ, 1996, TOXICOL APPL PHARM, V141, P288, DOI 10.1016/S0041-008X(96)80035-4
[3]  
Bardelmeijer HA, 2002, CANCER RES, V62, P6158
[4]   Functional expression and localization of P-glycoprotein at the blood brain barrier [J].
Bendayan, R ;
Lee, G ;
Bendayan, M .
MICROSCOPY RESEARCH AND TECHNIQUE, 2002, 57 (05) :365-380
[5]  
BOAZIZ C, 1991, PATHOL BIOL, V39, P789
[6]   Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems [J].
Bodor, N ;
Buchwald, P .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (2-3) :229-254
[7]   The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro [J].
Chandler, B ;
Almond, L ;
Ford, J ;
Owen, A ;
Hoggard, P ;
Khoo, S ;
Back, D .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (05) :551-556
[8]  
Choo EF, 2000, DRUG METAB DISPOS, V28, P655
[9]  
CISTERNINO S, 2003, AAPS ANN M EXP OCT 2
[10]   Functional expression of the multidrug resistance protein 1 in microglia [J].
Dallas, S ;
Zhu, XP ;
Baruchel, S ;
Schlichter, L ;
Bendayan, R .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (01) :282-290